about
Treating nausea and vomiting in palliative care: a reviewOndansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.Ion pair formation as a possible mechanism for the enhancement effect of lauric acid on the transdermal permeation of ondansetron.Comparative study between nalbuphine and ondansetron in prevention of intrathecal morphine-induced pruritus in women undergoing cesarean section.Treatment of nausea and vomiting in terminally ill cancer patients.Headache as a presenting feature in patients with serotonin syndrome: a case series.5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain.Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice.Use of an 8(1)3(2) asymmetrical factorial design for the in vitro evaluation of ondansetron permeation through human epidermis.Seasonal modulation of the 8-and 24-hour rhythms of ondansetron tolerance in mice.Gender differences in ondansetron pharmacokinetics in rats.Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting.A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
P2860
Q24635649-C0AE325E-CE28-445A-9A9D-00CE99C0E340Q30006159-96534577-8185-4D24-AA68-6210B1021499Q30967177-648D05EF-5C33-4DF0-B9A8-7564C276A44EQ36894630-00FF5BF7-9E2E-4D71-9FF0-4D8B519D12D7Q37354119-4DDE7427-B711-42D7-99A3-D4F7F958CCACQ38119391-9671CE3F-79A4-4853-93D3-8E1F3B991EEEQ38246665-87963EBC-B259-48DB-96D1-C9C00FF8C1D4Q39042372-37D0FEA6-E614-4E29-96D0-22BCC2F28A6AQ40774467-CD9E4DE8-A1B1-4DAB-93D3-CF3F596E301CQ41853014-27ECE97C-51D3-4E2A-941B-BA54D592A41CQ42940085-96E8BA1F-47C5-4FD0-AE13-3009F870FEAAQ44696606-A388F61D-20D1-4249-B0FC-2C8615E11A7BQ44786249-0E7AD5EC-DC49-4E3E-8742-C677840808D4Q46333551-D7BE6F74-CFA9-4F29-B1CA-00D109C4A7AFQ46433907-95764282-AA45-46EF-856F-FBF08B0F7DC8Q46812638-C6B325DE-0577-4A7D-A4EA-87251E9B297FQ47963518-83BDA034-0F0C-4FAC-BFE1-2BDE53F2EC71
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Clinical pharmacokinetics of ondansetron. A review.
@en
type
label
Clinical pharmacokinetics of ondansetron. A review.
@en
prefLabel
Clinical pharmacokinetics of ondansetron. A review.
@en
P2860
P1476
Clinical pharmacokinetics of ondansetron. A review.
@en
P2093
P2860
P304
P356
10.1111/J.2042-7158.1996.TB03973.X
P577
1996-08-01T00:00:00Z